Want to see SNY full AI Analyst Report?
SNY Stock Chart & Stats
$48.06
-$0.67(-1.34%)
At close: 4:00 PM EST
$48.06
-$0.67(-1.34%)
Day’s Range― - ―
52-Week Range$40.89 - $52.68
Previous CloseN/A
Volume824.98K
Average Volume (3M)3.63M
Market Cap
$105.30B
Enterprise Value$104.49B
Total Cash (Recent Filing)$5.54B
Total Debt (Recent Filing)$20.02B
Price to Earnings (P/E)19.1
Beta0.41
Next Earnings
Jul 30, 2026EPS Estimate
1.09Next Dividend Ex-DateN/A
Dividend Yield4.58%
Share Statistics
EPS (TTM)1.94
Shares Outstanding2,428,197,300
10 Day Avg. Volume3,397,546
30 Day Avg. Volume3,633,287
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.41
Price to Sales (P/S)2.15
P/FCF Ratio9.92
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue2.21
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda8.28
Forecast
1Y Price Target
$52.00Price Target Upside8.20% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)4.93
Revenue Forecast (FY)$56.45B
Bulls Say, Bears Say
Bulls Say
Leading Immunology Franchise And LaunchesDupixent's sustained blockbuster growth and multiple new approvals materially enlarge Sanofi's high-value specialty portfolio. Durable demand across multiple type-2 indications supports recurring revenue, stronger pricing power in immunology, and a reliable cash base to fund R&D and launches over the next several years.
Solid Balance Sheet And Capital AccessConservative leverage and substantial equity provide financial flexibility for acquisitions, late‑stage development and capital spending. Proven access to debt markets (recent multi‑tranche bond) plus strong liquidity reduce refinancing risk and support multi‑year investment in pipeline execution and manufacturing scale.
Pipeline Momentum And Regulatory ProgressBreakthrough designations and positive late‑stage readouts (venglustat, lunsekimig, efdoralprin alfa) accelerate development timelines and de‑risk commercial prospects in rare and specialty indications. This strengthens long‑term growth optionality and the probability of durable new revenue streams beyond current blockbusters.
Bears Say
Operating‑margin PressureWidening cost base despite top‑line growth indicates persistent margin headwinds from higher SG&A, integration or launch costs. If operating leverage does not return, profit conversion from revenue could remain constrained, limiting internal funding for R&D and reducing shareholder returns over the medium term.
Revenue Concentration Risk Around DupixentRapidly rising reliance on a single franchise increases exposure to competitive entrants, label changes, or demand shifts. Heavy concentration can amplify earnings volatility and strategic risk if competitors, biosimilars or reimbursement changes materially affect that product's uptake.
Regulatory And Political Uncertainty For VaccinesLeadership turnover and heightened political scrutiny of vaccines create a less certain regulatory backdrop for approvals and post‑market policies. For a company with a large vaccine business, shifting agency priorities or politicized reviews can delay launches, procurement decisions, or public immunization programs over multiple quarters.
Sanofi News
SNY FAQ
What was Sanofi SA’s price range in the past 12 months?
Sanofi SA lowest stock price was $40.89 and its highest was $52.68 in the past 12 months.
What is Sanofi SA’s market cap?
Sanofi SA’s market cap is $105.30B.
When is Sanofi SA’s upcoming earnings report date?
Sanofi SA’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Sanofi SA’s earnings last quarter?
Sanofi SA released its earnings results on Apr 23, 2026. The company reported $1.101 earnings per share for the quarter, beating the consensus estimate of $1.037 by $0.064.
Is Sanofi SA overvalued?
According to Wall Street analysts Sanofi SA’s price is currently Undervalued.
Does Sanofi SA pay dividends?
Sanofi SA pays a Annually dividend of $2.419 which represents an annual dividend yield of 4.58%. See more information on Sanofi SA dividends here
What is Sanofi SA’s EPS estimate?
Sanofi SA’s EPS estimate is 1.09.
How many shares outstanding does Sanofi SA have?
Sanofi SA has 2,428,197,300 shares outstanding.
What happened to Sanofi SA’s price movement after its last earnings report?
Sanofi SA reported an EPS of $1.101 in its last earnings report, beating expectations of $1.037. Following the earnings report the stock price went up 1.344%.
Which hedge fund is a major shareholder of Sanofi SA?
Currently, no hedge funds are holding shares in SNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanofi Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$52.00 (8.20% Upside)
$52.00 (8.20% Upside)
Blogger Sentiment
Bullish
SNY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 27.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.32%
12-Months-Change
Fundamentals
Return on Equity
14.41%
Trailing 12-Months
Asset Growth
8.30%
Trailing 12-Months
Company Description
Sanofi SA
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
SNY Company Deck
SNY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive picture: strong top-line growth (9.9% FY, 13.3% Q4), robust launch performance (EUR 5.7bn from new products), significant pipeline delivery and regulatory progress, improved margins and free cash flow, plus strategic BD/M&A activity. Notable challenges include a Phase III failure for tolebrutinib, a safety case in the amlitelimab program that will require monitoring, decreased Regeneron R&D reimbursements (offset partly by higher royalties), and some uncertainty in the U.S. vaccine schedule and vaccine sales in 2026. Overall, positives (growth, profitability, launches, pipeline replenishment and balance sheet flexibility) outweigh the lowlights, though execution and regulatory/safety risks remain important to monitor.View all SNY earnings summariesSNY Stock 12 Month Forecast
Average Price Target
$52.00
▲(8.20% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.65% Mutual Funds
0.03% Other Institutional Investors
97.94% Public Companies and Individual Investors